Rna Diagnostics' News - Ontario multi-centre clinical trial initiated, RDA™ receives significant interest at Triple Negative Breast Cancer Conference, economic study indicates RDA™ provides healthcare cost-savings.


Summer 2013

Ontario multi-centre clinical trial

Rna Diagnostics (RnaDx) has initiated an Ontario multi-centre clinical trial to assess both patient health outcomes and healthcare savings related to the use of RNA Disruption Assay™ (RDA™). Through the MaRS Excellence in Clinical Innovation and Technology Evaluation (EXCITE) program, The Toronto Health Economics and Technology Assessment (THETA) initiative will perform a full pre-market assessment of the RDA technology.  

The EXCITE program consists of a multi-centre clinical trial, a human factors study of biopsy procedures, a comprehensive health economics analysis of RDA healthcare savings and a qualitative study of patient and clinician attitudes toward RDA testing. The EXCITE program will help move RDA to clinic faster, and improve health outcomes for women undergoing breast cancer chemotherapy. The Honourable Deb Matthews, Minister of Health and Long-Term Care, announced the participation of RnaDx in the EXCITE program on May 30 in Toronto.

Read full news release

Dr. Ken Pritzker presents at Triple Negative Breast Cancer Conference

There was substantial positive interest in RnaDx’ RNA Disruption Assay™ (RDA™) at the Triple Negative Breast Cancer (TNBC) Conference, held in London, England in June. Dr. Ken Pritzker presented an abstract on RDA to the assembly of international breast cancer specialists. View abstract

Triple Negative Breast Cancer is an aggressive form of cancer that often affects young women. TNBC patients have poorer prognoses than other breast cancer patients.  There is a dire need for a test to accurately determine the efficacy of breast cancer chemotherapy for these patients. Given their poor prognoses it is important to rapidly assess TNBC patients’ response to therapy so that non-responders may be switched from ineffective therapies to ones that may improve their chances of survival.

RDA is positioned as a useful tool to aid management of therapy for TNBC patients.  

The TNBC Conference was attended by over 150 specialists from around the world who are involved in breast cancer treatment and have an interest in finding better treatment methods for this aggressive form of breast cancer.

RDA demonstrates healthcare cost-savings 

A preliminary economic analysis of the RNA Disruption Assay™ (RDA™) demonstrates it is a cost-effective treatment strategy compared to standard of care for individuals undergoing breast cancer chemotherapy. Rna Diagnostics presented an abstract of the analysis at the Applied Research in Cancer Control conference (ARCC) in Vancouver, British Columbia in May.

The healthcare economic analysis indicates that RDA increases patient survival and lowers treatment costs for patients undergoing breast cancer chemotherapy. The key factor driving the cost-effectiveness of RDA is the ability of the test to detect individuals who are not responding to breast cancer chemotherapy.

View abstract 

Rna Diagnostics' CEO Dr. Ken Pritzker (third from left) with Minister Deb Matthews (fourth from left) at EXCITE announcement.

In the News

The announcement by Minister Matthews that Rna Diagnostics is one of three participants in the MaRS EXCITE program, received wide interest. News of RnaDx’ selection was featured by MaRS, GenomeDaily News, Sudbury Star, and Life Sciences Ontario.

Personalized medicine panel

Dr. Ken Pritzker participated on a panel at OCE Discovery 2013 about the role of personalized medicine in disease diagnosis and treatment plans and what it takes to get technology transferred to the clinic. View video

Upcoming Events

October 5-7, 2013
Rna Diagnostics will present at the American Society of Clinical Oncology’s 5th International Symposium, Primary Systemic Treatment in the Management of Operable Breast Cancer, in Cremona, Italy.

Management Team

Ken Pritzker, MD, FRCPC
President & CEO

Amadeo Parissenti, PhD
Chief Scientific Officer

John Connolly, MBA
VP Corporate Development

John Jordan, MBA, CMA
Chief Financial Officer

Laura Pritzker, PhD
Principal Scientist

Clinical Advisory Board

Maureen Trudeau, MD, FRCPC,
Toronto, Canada

Gunter von Minckwitz, MD, PhD,
Frankfurt, Germany

Michael Untch, MD, PhD,
Berlin, Germany

Harry D. Bear, MD, PhD,
Richmond, VA, USA

Rna Diagnostics Inc. is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management.

Our mailing address is:
Rna Diagnostics Inc.
MaRS Centre, Heritage Building, 101 College Street, Suite HL20-4, Toronto, ON, Canada
Toronto, ON M5G 1L7

Add us to your address book
For more information contact:
John Connolly
VP Corporate Development